Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 6/20 | 0.49 |
| ▸ | MMP13 | P45452 | 6/20 | 0.49 |
| ▸ | MMP1 | P03956 | 4/20 | 0.49 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446197 | 0.91 | MMP13 (0.53) | MMP2MMP13MMP1MMP9PPARD | |
| SCHEMBL3568125 | 0.88 | MAPT (0.56) | MMP2MMP13MMP1MMP9PPARD | |
| SCHEMBL3348750 | 0.88 | MAPT (0.58) | CHRM3MMP2MMP13MMP1MMP9 | |
| SCHEMBL4440872 | 0.83 | MMP13 (0.52) | MMP2MMP13MMP1MMP9PPARD | |
| SCHEMBL4440854 | 0.83 | MAPT (0.46) | MMP2MMP13MMP1MMP9PPARD | |
| SCHEMBL4671246 | 0.82 | PPARD (0.47) | MRGPRX4PPARDPPARANR4A2PTGER4 | |
| SCHEMBL4444727 | 0.82 | MMP13 (0.50) | MMP2MMP13MMP1MMP9PPARD | |
| SCHEMBL3557950 | 0.81 | MAPT (0.55) | MRGPRX4MMP2MMP13MMP1MMP9 | |
| SCHEMBL4444299 | 0.80 | MAPT (0.49) | MMP2MMP13MMP1MMP9PPARD | |
| SCHEMBL3556746 | 0.78 | MAPT (0.72) | MRGPRX4MMP2MMP13MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | claimed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1663936-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | claimed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG AN | 2008-10-16 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1663936-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | GYS2, GYS1, PYGL | MRGPRX4 2501/4885CHRM3 2716/4885MMP2 811/4885 |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | MRGPRX4 1798/4885CHRM3 1589/4885MMP2 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.